Exjade FDA Approval History
FDA Approved: Yes (First approved November 2, 2005)
Brand name: Exjade
Generic name: deferasirox
Dosage form: Dispersible Tablets
Company: Novartis Pharmaceuticals Corporation
Treatment for: Hemosiderosis, Iron Overload
Exjade (deferasirox) is a once-daily oral iron chelator approved for the treatment of chronic iron overload due to blood transfusions, and non-transfusion-dependent thalassemia.
Development timeline for Exjade
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
